Vitamin D receptor activation and prevention of arterial ageing

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Patients with chronic kidney disease (CKD) exhibit significantly higher cardiovascular (CV) morbidity and mortality.
• Common comorbidities in CKD, including hypertension, diabetes, and mineral bone disease, contribute to elevated CV risk.
• Vitamin D deficiency is increasingly recognized as a critical factor exacerbating CV risk in the CKD population.

Purpose of the Study:

• To investigate the role of vitamin D deficiency in cardiovascular risk among chronic kidney disease patients.
• To evaluate the potential cardiovascular benefits of selective vitamin D receptor activators (VDRAs), such as paricalcitol, in CKD.
• To explore the impact of paricalcitol on specific CV risk factors including diabetic nephropathy, hypertension, and vascular calcification.

Main Methods:

• Review of recent data and studies focusing on vitamin D receptor (VDR) activation in CKD.
• Analysis of the effects of non-selective VDRA (calcitriol) versus selective VDRA (paricalcitol) on serum calcium and phosphate levels.
• Examination of clinical evidence regarding paricalcitol's influence on diabetic nephropathy, cardiac disease, hypertension, and vascular calcification in CKD.

Main Results:

• Non-selective VDRA, calcitriol, is associated with increased serum calcium and phosphate, potentially worsening CV risk in CKD.
• Emerging data suggest that selective VDRA, paricalcitol, may possess ameliorative cardiovascular effects in CKD patients.
• Paricalcitol shows potential for positive impact on diabetic nephropathy, cardiac disease, hypertension, and vascular calcification.

Conclusions:

• Vitamin D deficiency is a significant contributor to cardiovascular disease in chronic kidney disease.
• Selective VDRAs like paricalcitol represent a promising therapeutic strategy to mitigate cardiovascular risk in CKD patients.
• Further research into paricalcitol's role may offer new avenues for managing cardiovascular complications in CKD.